Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm

Drug development for chronic myelomonocytic leukemia (CMML) has failed to parallel the recent success observed in related myeloid neoplasms. To address these shortcomings, the US Food and Drug Administration (FDA) held a "Mini-symposium on CMML: Current State of the Art and Trial Design" in September 2023. This symposium brought together a panel of key FDA regulators and academic experts in CMML drug development to discuss challenges and provide perspectives on future drug development for this disease. The panel explored unique challenges that underlie the lack of therapeutic advances in CMML to date and discussed relevant topics such as clinical trial design, study end points, and key regulatory considerations. This article summarizes the key points of discussion from this symposium to facilitate advancements in the field.

Authors

Institutions

Publication Details

Journal
Blood
Published
2024-11-07
DOI
https://doi.org/10.1182/blood.2024025648
Citations
9
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
4.09
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm

Raphaël Itzykson, Yanxia Li, R. Angelo de Claro, Anthony Michael Hunter et al.
9 citations
Blood
Acute Myeloid Leukemia Research
4.09
article

Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm

Raphaël Itzykson, Yanxia Li, R. Angelo de Claro, Anthony Michael Hunter, Ruben A. Mesa, Eric Padron, Kelly J. Norsworthy, Marc Robert Theoret, Mrinal M. Patnaik, Chatchada Karanes, Elizabeth Pulte
article en
9 citations

Abstract

Drug development for chronic myelomonocytic leukemia (CMML) has failed to parallel the recent success observed in related myeloid neoplasms. To address these shortcomings, the US Food and Drug Administration (FDA) held a "Mini-symposium on CMML: Current State of the Art and Trial Design" in September 2023. This symposium brought together a panel of key FDA regulators and academic experts in CMML drug development to discuss challenges and provide perspectives on future drug development for this disease. The panel explored unique challenges that underlie the lack of therapeutic advances in CMML to date and discussed relevant topics such as clinical trial design, study end points, and key regulatory considerations. This article summarizes the key points of discussion from this symposium to facilitate advancements in the field.

BloodVol. 144(19)
Atrium Health Wake Forest Baptist (US), United States Food and Drug Administration (US), Mayo Clinic (US), Center for Drug Evaluation and Research (US), Emory University (US), Inserm (FR), Université Paris Cité (FR), WinnMed (US), Moffitt Cancer Center (US), Assistance Publique – Hôpitaux de Paris (FR), Hôpital Saint-Louis (FR), Wake Forest Baptist Comprehensive Cancer Center
Openalex Percentile: Top 5%
Acute Myeloid Leukemia Research
4.09
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.